Physician profile
Efthemios Raphtis
NPI 1356379259
$1,838.61
in general payments reported to CMS, 2019-2025
18 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $35.05 · 2021: $307 · 2022: $379 · 2023: $300 · 2024: $189 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $924.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $573.96 | 2021-2025 | Clareon, Rocklatan |
| Abbvie INC. | $288.12 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $197.72 | 2019-2024 | Cequa |
| Bausch & Lomb Americas INC. | $193.01 | 2025 | Envista Envy Iol, Miebo, Xiidra |
| Kala Pharmaceuticals, INC. | $84.91 | 2019-2021 | |
| Sight Sciences, INC. | $83.33 | 2023-2024 | Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $82.02 | 2019-2023 | Whitestar Signature, Tecnis Iol |
| Oyster Point Pharma, INC. | $55.98 | 2022-2024 | Tyrvaya |
| Allergan, INC. | $50.20 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $50.14 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $44.83 | 2019-2022 | |
| Biotissue Holdings INC. | $39.14 | 2022-2023 | |
| Thea Pharma INC. | $20.32 | 2025 | Iyuzeh |
| Horizon Therapeutics Plc | $18.01 | 2023 | Tepezza |
| New World Medical,INC. | $15.27 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.87 | 2020 | |
| Dompe US, INC. | $14.31 | 2022 | |
| Shire North American Group INC | $12.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Efthemios Raphtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.